Guerbet : Chiffre d’affaires du 1er semestre 2026.

Guerbet reports H1 2026 revenue of €379.2M (down 2.2% YoY, and -0.1% at constant FX and comparable scope), with the Americas up while Asia fell sharply (-14.0% YoY). For 2026, the group guides revenue between stable and slightly down at constant FX/scope and targets adjusted EBITDA margin ~8%, but expects strongly negative free cash flow of -€50M to -€70M due to Raleigh compliance costs (~€35M), higher CAPEX, and restructuring expenses. On financing, Guerbet secured a waiver for the net debt/EBITDA test at 30 Jun 2026-30 Jun 2027 and is seeking a refinancing by 31 Oct 2026, with the interim results pushed to 28 Sep 2026.

Analysis

This is less a demand story than a balance-sheet reset story. The operating print suggests the business can still hold share where supply normalizes, but the market should anchor on cash burn and funding terms, not on modest topline stabilization. In practice, every month the refi process drags on keeps equity valued as a residual claim on a levered, regulatory-disrupted asset base, which tends to suppress multiple expansion even if reported growth looks “fine.”

Competitively, the temporary rebound in the Americas likely reflects customers re-qualifying supply rather than a durable competitive win. That creates a near-term volume tailwind, but it also means peers with broader manufacturing redundancy can defend share if any operational slip recurs. The bigger structural pressure is Asia: reimbursement reform usually compresses premium pricing first, then forces portfolio rationalization, so the risk is not just lower sales but a worse mix and lower incremental margin.

The key catalysts are binary and calendar-driven: the rescheduled results, the October refinancing target, and the next FDA check. If refinancing lands on non-dilutive terms and Raleigh clears inspection without another step-up in remediation spend, downside can unwind quickly; if not, the path is toward covenant-driven dilution or asset disposals. Contrarian take: the market may be underestimating how much of the current weakness is timing noise in supply restoration, but that is not enough to offset funding risk until financing is signed.

Key Decisions for Investors

• Stay short / underweight GBT.PA into the late-September results and October refinancing window; the trade is a funding-risk short, not a revenue short. Falsify on a signed refi with no dilution and no incremental collateral.
• If liquidity allows, use a pair trade: short GBT.PA vs long PHIA.AS on a 1-3 month horizon to isolate balance-sheet stress from broader imaging demand. The thesis works if Guerbet’s spread risk widens while sector demand remains stable.
• Do not chase a long until the refinancing terms are known; any rally before the deal closes is likely headline-driven and fragile. Reassess only after terms disclose maturity extension, covenant relief, and cost of capital.
• Watch for a tactical cover signal if the company announces a clean refinance before the October deadline and confirms Raleigh normalization without extra capex. That would convert the equity from a distress option into an operating recovery story.